Arcadia Biosciences, Inc.
Description
Arcadia Biosciences, Inc. produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring. The company was incorporated in 2002 and is headquartered in Dallas, Texas.
About
CEO
Mr. Thomas J. Schaefer C.F.A.
Employees
21
Instrument type
Common Stock
Sector
Consumer Defensive
Industry
Packaged Foods
MIC code
XNCM
Address
5950 Sherry Lane, Dallas, TX 75225, United States
×
![Enlarged Chart]()
Oscillators
No data available
Summary
No data available
Moving Averages
No data available
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 11, 2025 | — | — | — | — |
| Aug 11, 2025 | — | — | — | — |
| May 7, 2025 | — | — | — | — |
| Mar 26, 2025 | — | — | — | — |
| Nov 13, 2024 | -0.81 | -1.18 | -0.37 | 45.68% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 0 | — | 0 |
| Average estimate | — | 0.00 | — | 0.00 |
| Low estimate | — | 0.00 | — | 0.00 |
| High estimate | — | 0.00 | — | 0.00 |
| Last year EPS | — | — | — | — |
[stock_revenue_estimate]
Growth estimates
Current qtr
—
Next qtr. (Mar 2025)
—
Current year
—
Next year (Dec 2025)
—
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 5.33M | 7.42M | 6.78M | 8.03M | 1.17M |
| Cost of revenue | 3.30M | 6.10M | 8.71M | 5.20M | 885,000 |
| Gross profit | 2.03M | 1.32M | -1.93M | 2.84M | 284,000 |
| Operating expense | |||||
| Research & development | 1.39M | 1.51M | 3.89M | 7.96M | 7.10M |
| Selling general and admin | 14.51M | 15.04M | 22.94M | 16.47M | 13.57M |
| Other operating expenses | — | — | — | — | — |
| Operating income | -13.87M | -15.23M | -28.76M | -21.59M | -20.38M |
| Non operating interest income | |||||
| Income | 695,000 | 289,000 | — | — | — |
| Expense | — | — | 20,000 | 47,000 | 5,000 |
| Other income expense | 13,000 | 4.13M | 12.64M | 15.49M | -7.78M |
| Pretax income | -13.16M | -10.81M | -16.13M | -6.15M | -28.87M |
| Tax provision | 8,000 | 14,000 | 2,000 | -124,000 | 2,000 |
| Net income | -13.99M | -15.61M | -16.13M | -6.03M | -28.87M |
| Basic EPS | -11.30 | -25.65 | -27.60 | -18.80 | -181.20 |
| Diluted EPS | -11.30 | -25.65 | -27.60 | -18.80 | -181.20 |
| Basic average shares | 1.24M | 599,389 | 532,015 | 248,975 | 159,077 |
| Diluted average shares | 1.24M | 599,389 | 532,015 | 248,975 | 159,077 |
| EBITDA | -13.97M | -19.18M | -31.01M | -20.19M | -20.43M |
| Net income from continuing op. | -13.99M | -15.61M | -16.13M | -6.03M | -28.87M |
| Minority interests | 5,000 | 236,000 | 1.47M | 1.37M | 68,000 |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 19.71M | 28.92M | 43.92M | 47.35M | 32.57M |
| Current assets | |||||
| Cash | — | — | — | — | — |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 6.52M | 20.64M | 28.69M | 14.04M | 8.42M |
| Other short term investments | 5.12M | — | — | 11.63M | 16.92M |
| Accounts receivable | 514,000 | 1.22M | 1.37M | 1.41M | 602,000 |
| Other receivables | — | — | — | — | — |
| Inventory | 1.96M | 2.32M | 4.43M | 3.81M | 1.79M |
| Prepaid assets | — | — | 900,000 | 811,000 | 712,000 |
| Restricted cash | — | — | — | — | — |
| Assets held for sale | 51,000 | 417,000 | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 807,000 | 795,000 | 900,000 | 811,000 | 712,000 |
| Non current assets | |||||
| Properties | 1.07M | 2.53M | 5.74M | 8.78M | 4.41M |
| Land and improvements | — | — | — | — | — |
| Machinery furniture equipment | 1.03M | 1.22M | 2.99M | 3.25M | 1.98M |
| Construction in progress | — | — | — | — | — |
| Leases | 1.59M | 1.59M | 2.31M | 2.23M | 2.02M |
| Accumulated depreciation | -2.51M | -2.81M | -5.66M | -4.89M | -4.64M |
| Goodwill | 39,000 | 40,000 | 484,000 | 1.19M | — |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | 39,000 | 40,000 | 484,000 | 370,000 | — |
| Investments and advances | — | — | — | — | — |
| Other non current assets | 3.52M | 956,000 | 2.67M | 5.51M | 372,000 |
| Total liabilities | 7.00M | 8.02M | 12.72M | 18.80M | 24.25M |
| Current liabilities | |||||
| Accounts payable | 801,000 | 905,000 | 1.41M | 726,000 | 492,000 |
| Accrued expenses | 1.61M | 1.95M | 2.23M | 3.38M | 4.19M |
| Short term debt | 852,000 | 1.01M | 1.07M | 1.86M | 635,000 |
| Deferred revenue | — | — | — | 8,000 | 42,000 |
| Tax payable | — | — | — | — | — |
| Pensions | — | — | — | — | — |
| Other current liabilities | 270,000 | 296,000 | 264,000 | 263,000 | 306,000 |
| Non current liabilities | |||||
| Long term debt | 155,000 | 1.01M | 2.22M | 7.49M | 1.60M |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | — | — | — | — | — |
| Derivative product liabilities | 1.26M | 806,000 | 3.39M | 2.71M | 14.94M |
| Other non current liabilities | 2.00M | 2.00M | 2.07M | 2.28M | 2.00M |
| Shareholders equity | |||||
| Common stock | 65,000 | 65,000 | 63,000 | 54,000 | 49,000 |
| Retained earnings | -271.84M | -257.86M | -226.49M | -211.83M | -207.17M |
| Other shareholders equity | 101,000 | — | — | — | 1,000 |
| Total shareholders equity | 12.70M | 20.90M | 31.20M | 28.55M | 8.33M |
| Additional paid in capital | 284.52M | 278.83M | 257.52M | 239.50M | 214.83M |
| Treasury stock | — | — | — | — | — |
| Minority interest | -138,000 | -133,000 | 103,000 | 827,000 | 621,000 |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||
| Net Income | -13.99M | -15.61M | -16.13M | -6.03M | -28.87M | -13.48M | -15.71M | -19.62M | -17.96M | -18.34M | -13.20M | -12.37M |
| Depreciation | 287,000 | 479,000 | 1.05M | 662,000 | 194,000 | 154,000 | 279,000 | 304,000 | 294,000 | 358,000 | 391,000 | 378,000 |
| Deferred Taxes | — | — | — | -107,000 | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | 717,000 | 1.11M | 1.54M | 2.04M | 2.29M | 1.55M | 1.47M | 1.06M | 1.39M | 976,000 | 1.28M | 1.25M |
| Other Non-Cash Items | 6.44M | 196,000 | 492,000 | -4.18M | -299,000 | 2.56M | 98,000 | 198,000 | 1.34M | 704,000 | 90,000 | — |
| Accounts Receivable | 184,000 | 592,000 | -40,000 | -1.12M | -434,000 | 1.07M | -703,000 | 255,000 | 634,000 | -293,000 | 210,000 | 162,000 |
| Accounts Payable | -522,000 | -757,000 | -372,000 | -580,000 | 2.10M | 176,000 | 87,000 | -19,000 | 125,000 | -216,000 | 421,000 | 197,000 |
| Other Assets & Liabilities | -2.42M | 1.14M | -2.55M | -9.84M | -1.55M | -55,000 | -628,000 | 802,000 | -360,000 | -663,000 | -964,000 | -1.20M |
| Operating Cash Flow | -9.30M | -12.86M | -16.02M | -19.15M | -26.57M | -8.03M | -15.10M | -17.03M | -14.53M | -17.47M | -11.77M | -11.58M |
| Investing Activities | ||||||||||||
| Capital Expenditures | 110,000 | 848,000 | -988,000 | -2.33M | -1.46M | -240,000 | -75,000 | -231,000 | -141,000 | -141,000 | -100,000 | -285,000 |
| Net Intangibles | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Acquisitions | 569,000 | 569,000 | -4.25M | 2.65M | — | — | — | — | — | — | — | — |
| Purchase of Investments | -7.53M | — | — | -1.29M | -28.36M | -29.89M | -19.41M | -41.39M | -48.72M | -1.45M | -500,000 | — |
| Sale of Investments | 2.50M | — | 21.85M | 18.25M | 21.45M | 24.15M | 66.66M | 36.32M | 2.50M | — | — | — |
| Investing Cash Flow | -4.34M | 1.42M | 16.61M | 17.28M | -8.37M | -5.98M | 47.18M | -5.30M | -46.36M | -1.59M | -600,000 | -285,000 |
| Financing Activities | ||||||||||||
| Long-Term Debt Issuance | — | — | — | 3.11M | — | — | — | — | 45.00M | — | 8.60M | 8.00M |
| Long-Term Debt Payments | — | — | -2.15M | -34,000 | -8,000 | — | -26.13M | — | -36.12M | -1.16M | -765,000 | — |
| Other Financing Charges | -497,000 | -488,000 | -1.16M | 63,000 | -796,000 | -2.49M | — | -46,000 | -8.60M | -1.59M | -22,000 | — |
| Financing Cash Flow | 5.50M | 4.51M | 21.84M | 11.14M | 6.70M | 7.51M | -26.13M | -46,000 | 68.51M | 30.10M | 7.83M | 8.00M |
| Other Cash Details | ||||||||||||
| End Cash Position | 6.52M | 20.64M | 28.69M | 16.04M | 8.42M | 12.00M | 9.13M | 2.01M | 23.97M | 16.57M | 2.84M | 5.35M |
| Income Tax Paid | — | — | 1,000 | 1,000 | 2,000 | 34,000 | 2,000 | 29,000 | 149,000 | 103,000 | 85,000 | 244,000 |
| Interest Paid | — | 1,000 | 25,000 | 10,000 | 4,000 | — | 746,000 | 1.03M | 2.05M | 736,000 | 514,000 | 150,000 |
| Free Cash Flow | -15.30M | -14.05M | -26.88M | -32.55M | -18.68M | -13.88M | -14.04M | -17.29M | -15.26M | -14.94M | -9.85M | -9.87M |
Top Institutional Holders
| Holder | Date Reported | Shares | Value | % Held |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | Sep 30, 2024 | 14,038 | 67,382 | 1.03% |
| Fidelity Extended Market Index Fund | Nov 30, 2024 | 7,527 | 36,129 | 0.55% |
| Fidelity Total Market Index Fund | Nov 30, 2024 | 1,626 | 7,804 | 0.12% |
| Fidelity Series Total Market Index Fund | Nov 30, 2024 | 1,006 | 4,828 | 0.07% |
Article
ARCADIA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Arcadia Biosciences, Inc. - RKDA
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Arcadia Biosciences, Inc. (NasdaqCM: RKDA) and Roosevelt Resources LP. Pursuant to the terms of the agreement, upon completion of the Merger, Arcadia stockholders are expected to own approximately 10% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are a.
Dec 11, 2024
Article
Arcadia Biosciences to Merge With Roosevelt, Shares Surge 105%
RKDA inks deal with Roosevelt to become a new entity, Roosevelt Resources, with Roosevelt as the majority shareholder.
Dec 9, 2024
Article
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Arcadia Biosciences, Inc. - RKDA
NEW YORK , Dec. 6, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Arcadia Biosciences, Inc. (NASDAQ: RKDA ), relating to the proposed merger with Roosevelt Resources LP.
Dec 7, 2024
